REG - Arecor Therapeutics - Posting of Annual Report and Notice of AGMm

Arecor TherapeuticsAnnouncement

Yesterday 16:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260428:nRSb2689Ca&default-theme=true

RNS Number : 2689C  Arecor Therapeutics PLC  28 April 2026

 

Arecor Therapeutics plc

("Arecor" or the "Company")

 

Posting of Annual Report and Notice of AGM

Cambridge, UK, 28 April 2026: Arecor Therapeutics plc (AIM: AREC), a clinical
stage biotech company developing superior therapeutics that can reduce
treatment burden and improve outcomes for people living with diabetes, obesity
and other cardiometabolic diseases, has today published and posted to
shareholders its Annual Report and Accounts for the year ended 31 December
2025.

The Company has also shared the Notice of the Annual General Meeting ("AGM")
which will be held on Thursday, 28 May at 9.30am BST at the offices of
Covington & Burling LLP, 22 Bishopsgate, London EC2N 4BQ.

In order to ensure that shareholders are able to follow the proceedings of the
AGM without attending in person, the Company will provide access online via
the Investor Meet Company (https://www.investormeetcompany.com/) platform.

Please note that shareholders will not be able to vote online at the AGM via
the platform and are therefore requested to submit their votes via proxy, as
early as possible. Shareholders that wish to attend the AGM remotely should
register for the event in advance by emailing maggie.mcconnell@arecor.com

The Annual Report and Accounts and Notice of AGM are also now available to
view and download from the Company's website
at https://arecor.com/investor-centre/shareholder-information/
(https://arecor.com/investor-centre/shareholder-information/)

-ENDS-

For more information, please contact:

 Arecor Therapeutics plc

Dr Sarah Howell, Chief Executive Officer

David Ellam, Chief Financial Officer            +44 (0) 1223 426060

                                                  info@arecor.com
 Singer Capital Markets Advisory LLP

(NOMAD and Broker)

 Phil Davies, James Fischer                       +44 (0) 20 7496 3000
 Vigo Consulting (Financial Communications)       +44 (0) 20 7390 0230
 Melanie Toyne-Sewell, Rozi Morris

                                                  arecor@vigoconsulting.com
 Vida Strategic Partners (US Investor Relations)  +1 (415) 675-7401

 Stephanie Diaz                                   sdiaz@vidasp.com

 

Notes to Editors

About Arecor

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company
developing superior therapeutics that can reduce treatment burden and improve
outcomes for people living with diabetes, obesity and other cardiometabolic
diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL)
ultra-rapid-acting insulin in development. Arecor has signed an initial
strategic partnership with Sequel Med Tech, a leading automated insulin
delivery (AID) system company to co-develop AT278 in combination with Sequel's
twiist™ AID system. Clinically de-risked, AT278 is designed to transform AID
systems, addressing a multi-billion dollar diabetes market. Arecor is also
developing a novel oral delivery platform for peptides with GLP-1 receptor
agonists its first validation target.

The Company is listed on AIM (AIM: AREC) and is based in Cambridge, UK. For
further details please see www.arecor.com (http://www.arecor.com/) .

Arecor® and Arestat® are registered trademarks of Arecor Limited.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSAKFBBPBKDBQB



            Copyright 2019 Regulatory News Service, all rights reserved